GLP-1 Drug Revolution: Surge, Supply, Coverage, and New Uses

GLP-1 agonist use has surged 140% (2022-2024), driving a 34% drop in bariatric surgery. Supply shortages in Namibia and a black market for unapproved retatrutide highlight access issues. Employers like Starbucks are cutting coverage, while new consensus guidance on nutrition for incretin therapy and emerging use for PCOS are shaping the landscape.